Size: | Price | Quantity | |
---|---|---|---|
10 mg | $48.00 | ||
50 mg | $200.00 |
Anagrelide HCl (58579-51-4) is a potent and selective phosphodiesterase (PDE3) inhibitor, IC50=36 nM).1 Inhibits platelet production by disrupting megakaryocyte maturation2 via a mechanism which is independent of PDE3 inhibition3. Clinically useful agent for conditions requiring platelet lowering therapy.4,5
References/Citations:
1) Gilespie et al. (1988), Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity; Biochem. Pharmacol. 37 2866
2) Mazur et al. (1992), Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans; Blood, 79 1931
3) Wang et al. (2005), Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures; Br. J. Pharmacol., 146 324
4) Barbui et al. (2012), Front-line therapy in polycythemia vera and essential thrombocythemia; Blood Rev., 26 205
5) Chen et al. (2012), Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis; Jpn. J. Clin. Oncol., 42 761
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Anagrelide HCl (58579-51-4) is a potent and selective phosphodiesterase (PDE3) inhibitor, IC50=36 nM).1 Inhibits platelet production by disrupting megakaryocyte maturation2 via a mechanism which is independent of PDE3 inhibition3. Clinically useful agent for conditions requiring platelet lowering therapy.4,5
References/Citations:
1) Gilespie et al. (1988), Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity; Biochem. Pharmacol. 37 2866
2) Mazur et al. (1992), Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans; Blood, 79 1931
3) Wang et al. (2005), Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures; Br. J. Pharmacol., 146 324
4) Barbui et al. (2012), Front-line therapy in polycythemia vera and essential thrombocythemia; Blood Rev., 26 205
5) Chen et al. (2012), Platelet-lowering therapy with anagrelide as an adjuvant therapy for treatment of primary pulmonary neoplasm-associated extreme thrombocytosis; Jpn. J. Clin. Oncol., 42 761
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.